Patients with breast cancer and coexisting chronic lymphocytic leukemia (CLL) present with more advanced disease and poorer survival compared with those without CLL, according to the results of a...
Researchers found that the combination of benmelstobart, chemotherapy, and anlotinib yields improved response and progression-free survival in patients with advanced or recurrent endometrial cancer,...
The FDA announced the approval of darolutamide for treating metastatic castration-sensitive prostate cancer. This review was conducted under Project Orbis, which allows for concurrent submission and review...
The results of a large retrospective analysis noted significant age-related differences in the germline landscape of endometrial cancer. This study was presented as a poster at the 2025 American Society of...
Acalabrutinib demonstrated a significantly safer cardiovascular profile and lower mortality risk compared with chemoimmunotherapy in patients with chronic lymphocytic leukemia based on a large retrospective...
A phase 2 study evaluating the safety and efficacy of letrozole, abemaciclib, and metformin in treating estrogen receptor–positive recurrent endometrial cancer highlights promising outcomes in a select...
A post hoc analysis of the DUO-E trial evaluated how durvalumab and maintenance olaparib influenced circulating tumor DNA dynamics in first-line endometrial cancer treatment.
A retrospective analysis presented at the American Society of Clinical Oncology 2025 Annual Meeting suggests that higher tumor mutational burden (TMB) may be linked to longer progression-free survival in...
The 2025 American Society of Clinical Oncology guideline update redefines the role of sentinel lymph node biopsy (SLNB) in early-stage breast cancer. Building on evidence from major trials, the update...
